FDA Exacts Tougher Labels For Anti-Psychotic Drugs

Law360, New York (June 16, 2008, 12:00 AM EDT) -- The U.S. Food and Drug Administration has opted for a stiffer warning for an older class of anti-psychotic drugs that includes Johnson & Johnson's Risperdal, concerned that even this “conventional” line of medications can increase the risk of death when used to treat dementia patients.

On Monday, the FDA demanded that manufacturers make safety-related changes to the labeling of this group of medications, pointing to a higher risk of death associated with this particular off-label use.

"It is important that health care professionals and consumers have...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.